Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Rating of “Moderate Buy” by Analysts

Immix Biopharma, Inc. (NASDAQ:IMMX) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $20.7143.

A number of research analysts have recently issued reports on IMMX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Bank of America started coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective for the company. HC Wainwright lifted their target price on shares of Immix Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Citigroup assumed coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating on the stock. Finally, Needham & Company LLC began coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $21.00 price target on the stock.

Immix Biopharma Price Performance

Shares of IMMX opened at $9.54 on Thursday. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $12.14. The company has a market capitalization of $519.07 million, a price-to-earnings ratio of -10.37 and a beta of 0.11. The business has a 50-day moving average of $9.34 and a 200-day moving average of $8.78.

Immix Biopharma (NASDAQ:IMMX) last announced its earnings results on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, sell-side analysts anticipate that Immix Biopharma will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Allworth Financial LP acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $30,000. Everhart Financial Group Inc. acquired a new stake in shares of Immix Biopharma during the 2nd quarter worth approximately $103,000. Mathes Company Inc. bought a new stake in shares of Immix Biopharma in the 4th quarter valued at $56,000. Balyasny Asset Management L.P. bought a new stake in shares of Immix Biopharma in the 4th quarter valued at $67,000. Finally, Kera Capital Partners Inc. acquired a new position in shares of Immix Biopharma during the 4th quarter valued at $68,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.